Corcept Therapeutics Incorporated (NASDAQ:CORT) shares soared 21.95% to $113.35 after the bell on Wednesday following the announcement of second-quarter results, where both revenue and earnings per share topped analyst estimates.
Revenue and EPS Sail Past Analyst Targets The California-based biopharmaceutical company reported second-quarter revenue of $256.1 million for the period ended June 30, up from $194.4 million a year earlier.
This revenue beat analyst estimates of $219.32 million by 16.8%.
EPS probably draws the most attention for investor optimism.
It came in at $0.36, compared with the expected $0.02, representing a 1,700% beat.
